MORGAN STANLEY PLC/CALL/BIOGEN IDEC/270/0.01/20.06.25 | Real-time Bid/Ask 03:16:13 2024-07-02 am EDT | ||
| 0.203 EUR / 0.21 EUR | +1.97% |
|
| Current month | +3.57% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-01 | 0.203 | +3.57% |
| 24-06-28 | 0.196 | +6.52% |
| 24-06-27 | 0.184 | +10.18% |
| 24-06-26 | 0.167 | -2.91% |
| 24-06-25 | 0.172 | -6.52% |
Delayed Quote Börse Stuttgart
Last update July 01, 2024 at 02:42 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | Morgan Stanley |
| WKN | MG6CD6 |
| ISIN | DE000MG6CD61 |
| Date issued | 2024-06-20 |
| Strike | 270 $ |
| Maturity | 2025-06-20 (354 Days) |
| Parity | 100 : 1 |
| Emission price | 0.21 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.231 € |
|---|---|
| Lowest since issue | 0.167 € |
| Spread | 0.007 € |
| Spread % | 3.33% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
35
Last Close Price
231.8
USD
Average target price
283.2
USD
Spread / Average Target
+22.17%
- Stock Market
- Warrants
- Warrant
